Loading... Please wait...

New York State Exchange and Medicaid Expansion - Implications for Pharmaceutical Manufacturers

Price:
$4,500.00
Quantity:


Product Description

RELEASE DATE: October 2012  |  PRICE: $4,500  | Pages 20

New York has a large uninsured populations and challenging small and individual group markets that have weathered significant premium increases over time.  It has a large urban market dominated by entrenched insurers and rural populations with low managed care penetration.  New York’s transition to Managed Medicaid and the void of insurers within the small group market in the state set the stage for significant competition for new eligibles expected to flow into these insurer models. 

This report has been structured for Managed Care decision makers like yourself-to assist in creating a blueprint for your organization's post-ACA market access strategies in key geographies. As key states begin to take ownership of the post-ACA access and coverage model, you will face a diverse set of market dynamics that require insight into which insurers are likely to play a prominent role in the new landscape and what the impact of their role means for access and coverage. 

Reasons to Purchase New York State Exchange and Medicaid Expansion - Implications for Pharmaceutical Manufacturers

Pharmspective’s assessment of the post-ACA market access landscape in New York will help you understand: 

• Opportunities and threats to market access and coverage of pharmaceuticals, based on assessment of benchmark plans 

• The role of MLRs in potential Payer Exchange contracting aggressiveness among key insurers in the state

• Analysis of Medicaid Expansion including how the state may decide to leverage the potential upside from its large uninsured population with insurers

• A Situation Assessment of the post-ACA landscape for insurers in New York including what their current competitive position across books-of-business within the state tell us about their future market prospects

Our report is a first-of-its kind analysis of the likely market dynamics that will determine how the New York market access landscape will evolve as key ACA provisions take hold.

About Pharmspective: 

Pharmspective, LLC creates Data Visualization tools that simplify the understanding of key insights derived from its proprietary primary and secondary market research on Market Access for Specialty Therapeutics. Our research studies examine clinical decision-making, drug acquisition, access and reimbursement, and patient administration for specialty drugs. Our data visualization tools provide state-of-the-art user interfaces that allow our customers to look at market intelligence from a wide range of perspectives with PC-based and Tablet applications. Pharmspective’s Healthcare Reform team provides insights into the Affordable Care Act through its proprietary ClearView™ state-of-the-art-app on iPad® or PC. Our ACA Market Access Reports detail the impact of the ACA on key states and HealthCareReformInsider.com provides the latest news on the ACA.

The company maintains offices in New York City and St. Louis, MO.

Follow us!

Pharmspective on Twitter athttps://twitter.com/Pharmspective

HealthCareReformInsider.com on Twitter at https://twitter.com/HCRinsider

 

ASK A QUESTION ABOUT THIS REPORT